1 of 1
Story summary
- HHS Secretary Robert F. Kennedy Jr. announced the FDA will review peptides for potential inclusion on the 503A bulk list.
- Hims & Hers Health shares surged after the announcement.
- The move could open revenue streams for the company, which has invested in peptide manufacturing.
- Analysts say any impact may not occur until 2027 due to declining net income and Amazon Pharmacy competition.
- Hims aims to transition peptides into regulated care.
